Stockscreener 앱 받기
7.27
2.02%
-0.15
전일 마감가:
$7.42
열려 있는:
$7.715
하루 거래량:
193.07K
Relative Volume:
0.87
시가총액:
$447.13M
수익:
-
순이익/손실:
$-38.61M
주가수익비율:
-7.3308
EPS:
-0.9917
순현금흐름:
$-29.20M
1주 성능:
+2.25%
1개월 성능:
+1.39%
6개월 성능:
+28.22%
1년 성능:
+81.30%
1일 변동 폭
$7.05
$7.715
1주일 범위
$7.05
$8.13
52주 변동 폭
$3.6669
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Compare EPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.27 | 447.13M | 0 | -38.61M | -29.20M | -0.9917 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 개시 | William Blair | Outperform |
| 2025-07-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-26 | 개시 | H.C. Wainwright | Buy |
| 2025-06-16 | 개시 | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | 개시 | Craig Hallum | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
모두보기
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
Eupraxia reports endoscopy score data from EoE trial By Investing.com - Investing.com Australia
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia Pharmaceuticals Highlights Strong EP-104GI EoE Data From RESOLVE Trial at DDW - TipRanks
Why 20 shots matter: Eupraxia links fuller dosing to lower EoE scope scores - Stock Titan
Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co. - Moomoo
Eupraxia Pharmaceuticals: Tambiah to Succeed Mark Kowalski - Moomoo
Eupraxia Pharmaceuticals Names New Chief Medical Officer to Steer Late-Stage Pipeline - TipRanks
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer - Investing News Network
Eupraxia appoints Dr. Jeymi Tambiah as chief medical officer - Investing.com UK
Eupraxia appoints Dr. Jeymi Tambiah as chief medical officer By Investing.com - Investing.com Nigeria
Surgeon-scientist Jeymi Tambiah joins Eupraxia as CMO - Stock Titan
Osteoarthritis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observe | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corp - Barchart.com
A Quick Look at Today's Ratings for Eupraxia Pharmaceuticals(EPRX.US), With a Forecast Between $11 to $16 - Moomoo
Eupraxia Pharmaceuticals (EPRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Eupraxia Pharmaceuticals Shares Drop After $70 Million Offering Pricing - MSN
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting - Sahm
EPRX Eupraxia Pharmaceuticals posts wider than expected Q4 2025 loss on zero revenue, shares dip nearly 1 percent. - Cổng thông tin điện tử Tỉnh Sơn La
Eupraxia Pharmaceuticals Inc. - Mena FN
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Receives Buy Rating from HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals to Showcase EP-104GI Data at Digestive Disease Week 2026 - TipRanks
EP-104GI esophagitis data and DDW investor event for Eupraxia (TSX: EPRX) - Stock Titan
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Investing News Network
Eupraxia Posts Strong 36-Week EoE Data From Highest-Dose Cohort in RESOLVE Trial - TipRanks
Experimental esophagus treatment kept symptoms in remission for 36 weeks - Stock Titan
Canadian Investment Regulatory Organization Trading Halt – EPRX.WT.A - Weekly Voice
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to "Sell" at Wall Street Zen - MarketBeat
Eupraxia Pharmaceuticals (EPRX) Stock: Trendline Structure (Selling Pressure) 2026-04-16Expert Entry Points - Cổng thông tin điện tử tỉnh Lào Cai
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences - TipRanks
Eupraxia (EPRX) to showcase Diffusphere pipeline at April investor events - Stock Titan
Eupraxia Pharmaceuticals (EPRX) schedules June 18, 2026 annual meeting - Stock Titan
EPRX Price Today: Eupraxia Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences - Investing News Network
Eupraxia's April 21 Toronto conference presentation will be webcast - Stock Titan
Is Eupraxia Pharmaceuticals (EPRX) Stock tied to economic cycles | Price at $7.12, Up 3.72%Trading Ideas - Newser
New Highs: Can VLYPP weather a recessionTrade Performance Summary & AI Driven Price Forecasts - baoquankhu1.vn
Top iBio (IBIO) Competitors 2026 - MarketBeat
Whats the beta of Eupraxia Pharmaceuticals Inc stock2026 Top Gainers & Technical Pattern Recognition Alerts - baoquankhu1.vn
Eupraxia Pharmaceuticals Inc. (EPRX) - Minichart
Institution Moves: What are Eupraxia Pharmaceuticals Incs recent SEC filings showing2026 EndofYear Setup & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
How does Eupraxia Pharmaceuticals (EPRX) Stock compare to competitors | Price at $6.77, Down 4.65%Profit Surge - Newser
Can Eupraxia Pharmaceuticals (EPRX) Stock Go Higher | Price at $7.10, Down 0.98%Shared Trade Ideas - Newser
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
New strong sell stocks for April 2nd - MSN
New Strong Sell Stocks for April 2nd - Yahoo Finance
ETFs Investing in Eupraxia Pharmaceuticals, Inc. Stocks - TradingView
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 26.3% in March - MarketBeat
Eupraxia Pharmaceuticals Projected to Post Earnings on Tuesday - National Today
Eupraxia Pharmaceuticals Inc (EPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):